ArticleBMJ public health2026
Short-term and long-term risk of death and readmission among adults aged 50+ years admitted with severe acute respiratory infections due to COVID-19, influenza or RSV in Denmark, 2022-2025.
Article in BMJ public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Respiratory infections due to COVID-19, influenza and respiratory syncytial virus (RSV) are common causes of morbidity and mortality among adults. We aimed to examine the incidence, severity and mortality of the three viruses among Danish hospitalised adults during three postpandemic years to evaluate the relative impact at population level. Methods: We included individuals aged 50 years and older admitted with a severe acute respiratory infection (SARI) due to COVID-19, influenza A or RSV between 23 May 2022 and 18 May 2025. Patients were identified from the national surveillance system for SARI through a combination of relevant International Statistical Classification of Diseases and Related Health Problems-10th edition diagnosis codes combined with a positive molecular test for either SARS-CoV-2, influenza A or RSV. Weekly incidence rates were calculated as number of cases per 100 000 population. For severity indicators, we analysed 30-day in-hospital mortality; 90-day postdischarge mortality; provision of intensive care treatment within 30 days of admission and 90-day risk of readmission. Results: Weekly incidence rates were higher for COVID-19 during the winter seasons of 2022/2023 and 2023/2024 than for influenza A and RSV, while influenza A dominated during the winter season of 2024/2025. In-hospital mortality across the three study seasons was similar for all three pathogens, while postdischarge mortality at 90 days after discharge was markedly higher for patients with COVID-19, with risk ratios and 95% CIs of 1.49 (1.38 to 1.61) compared with patients with influenza A and 1.36 (1.20 to 1.55) compared with patients with RSV. The risk ratios of readmission at 90 days were similarly higher for patients with COVID-19. Conclusions: Although the population-level impact of COVID-19 declined during three postpandemic years, adult patients admitted with COVID-19 consistently faced a higher risk of readmission and a higher mortality during the first 90 days after discharge compared with patients admitted with influenza A or RSV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.